ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure (PARACYS-RV)
Prospective Comparison of ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
Sponsor: Montreal Heart Institute
Terminated
The trial was prematurely terminated due to safety concerns.
Other terminated trials from Montreal Heart Institute
This NA trial investigates Heart Failure and Systemic Right Ventricle and is currently terminated or withdrawn. Montreal Heart Institute leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Apr 2024 — Jul 2024 [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
-
Jan 2023 — Apr 2024 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
May 2022 — Jan 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Dec 2021 — May 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Montreal Heart Institute
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .